早孕期高体重指数与妊娠早期和中期血管生成生物标志物改变相关
该研究为美国多中心前瞻性观察队列研究的二次分析,纳入2363名初产妇,评估早孕期体重指数与可溶性fms样酪氨酸激酶-1、胎盘生长因子及两者比值的关系。早孕期高体重指数与整个早孕期较低的可溶性fms样酪氨酸激酶-1浓度相关,并与胎盘生长因子升高幅度减小及孕中期比值升高相关。
要点
- 早孕期高体重指数与孕早期和孕中期较低的可溶性fms样酪氨酸激酶-1浓度持续相关。
- 体重指数每增加1单位,胎盘生长因子在孕早期至孕中期的平均升高幅度减少4.4 pg/mL(95%CI -3.6至-5.2)。
- 与正常体重组相比,II级或III级肥胖组孕中期可溶性fms样酪氨酸激酶-1与胎盘生长因子比值显著更高(P<.001)。
核心结论
- 早孕期高体重指数与整个早孕期较低的可溶性fms样酪氨酸激酶-1和胎盘生长因子浓度相关。
- 母亲体重与孕早期可溶性fms样酪氨酸激酶-1与胎盘生长因子比值呈负相关,与孕中期该比值呈正相关,驱动因素为孕早期至孕中期胎盘生长因子升高幅度减小。
- II级或III级肥胖女性孕中期可溶性fms样酪氨酸激酶-1与胎盘生长因子高比值(与胎盘功能障碍相关)的风险增加。
研究设计与样本
- 研究为美国多中心前瞻性观察队列研究内现有子研究的二次分析,对象为初产妇。
- 收集孕早期和孕中期母血样本、孕早期体重指数及人口学、生活方式和妊娠结局数据。
- 在孕6至13周和孕16至22周测量可溶性fms样酪氨酸激酶-1和胎盘生长因子浓度,对象包括发生不良妊娠结局的病例(孕37周前分娩、子痫前期或子痫、出生体重低于胎龄第5百分位或死产)和无这些结局的对照。
- 采用多变量混合效应线性回归模型估计体重指数与两个时间点血管生成生物标志物的关联,并评估孕早期至孕中期生物标志物浓度平均变化。
- 采用logistic回归模型估计孕中期可溶性fms样酪氨酸激酶-1与胎盘生长因子高比值(使用临床既定风险预测界值)的风险。
主要发现
- 2363名女性(1467例不良妊娠结局和896例对照)有血管生成生物标志物和早孕期体重指数数据。
- II级或III级肥胖组孕早期胎盘生长因子浓度较低(P<.001);超重组、I级肥胖组和II级或III级肥胖组孕中期胎盘生长因子浓度较低(P<.001)。
- 早孕期体重指数每增加1单位,胎盘生长因子在孕早期至孕中期的平均升高幅度减少4.4 pg/mL(95%CI -3.6至-5.2)。
- 与正常体重指数组相比,超重组、I级肥胖组和II级或III级肥胖组孕早期可溶性fms样酪氨酸激酶-1与胎盘生长因子比值平均显著更低(P<.05),II级或III级肥胖组孕中期该比值显著更高(P<.001)。
- 体重指数每增加1单位,可溶性fms样酪氨酸激酶-1与胎盘生长因子比值在孕早期至孕中期的平均升高幅度增加0.5(95%CI 0.3-0.7);单变量分析中,II级或III级肥胖组孕中期比值≥38的可能性是正常体重组的3.13倍(95%CI 1.15-8.49)。
关键数值与推荐
- 孕中期可溶性fms样酪氨酸激酶-1与胎盘生长因子比值高风险界值为≥38。
- 体重指数分类包括正常体重、超重、I级肥胖和II级或III级肥胖。
- 不良妊娠结局定义包括孕37周前分娩、子痫前期或子痫、出生体重低于胎龄第5百分位或死产。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is associated with various placenta-mediated adverse pregnancy outcomes, including preeclampsia, preterm birth, and stillbirth. Mechanisms linking obesity with placental dysfunction are not completely understood. OBJECTIVE: This study aimed to examine the relationship between early pregnancy body mass index and placental angiogenic biomarkers soluble fms-like tyrosine kinase-1, placental growth factor, and the soluble fms-like tyrosine kinase-1-to-placental growth factor ratio. STUDY DESIGN: We conducted secondary analyses of an existing substudy within a multisite, prospective observational cohort study of nulliparous pregnant women in the United States. First- and second-trimester maternal blood samples, first-trimester body mass index, and demographic, lifestyle, and pregnancy outcomes data were collected. Soluble fms-like tyrosine kinase-1 and placental growth factor concentrations were measured at 6 to 13 and 16 to 22 weeks of gestation for women (cases) who experienced one of several adverse pregnancy outcomes (delivery at <37 weeks of gestation, preeclampsia or eclampsia, birthweight for gestational age <5th percentile, or stillbirth) and for those who had none of those outcomes (controls). We used multivariable mixed-effects linear regression models to estimate the association of body mass index with angiogenic biomarkers at both time points. We evaluated mean change between first- and second-trimester biomarker concentrations using multivariable linear regression models. Lastly, we used logistic regression models to estimate the risk of a high second-trimester soluble fms-like tyrosine kinase-1-to-placental growth factor ratio, using clinically established cutoffs for risk prediction. RESULTS: Angiogenic biomarker and early pregnancy body mass index data were available for 2363 women (1467 with adverse pregnancy outcomes and 896 controls). High early pregnancy body mass index was associated with consistently lower soluble fms-like tyrosine kinase-1 concentrations across the first and second trimesters of pregnancy. We found lower first-trimester placental growth factor concentrations in the group with class II or III obesity (P<.001) and lower second-trimester placental growth factor concentrations among groups who were overweight, with class I obesity, and class II or III obesity (P<.001). For every unit increase in early pregnancy body mass index, there was a -4.4 pg/mL (95% confidence interval, -3.6 to -5.2) smaller mean increase in placental growth factor concentrations between the first and second trimesters of pregnancy. These differences resulted in significantly lower mean first-trimester soluble fms-like tyrosine kinase-1-to-placental growth factor ratios among groups who were overweight, with class I obesity, and class II or III obesity (P<.05) and in a significantly higher second-trimester soluble fms-like tyrosine kinase-1-to-placental growth factor ratio among the group with class II or III obesity (P<.001), compared with the group with normal body mass index. Each unit of increase in body mass index was associated with a 0.5 (95% confidence interval, 0.3-0.7) greater mean increase in the soluble fms-like tyrosine kinase-1-to-placental growth factor ratio between the first and second trimesters of pregnancy. In stratified analyses, associations between body mass index and angiogenic biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor were similar in nonadverse pregnancy outcome and adverse pregnancy outcome subgroups, whereas associations between body mass index and the soluble fms-like tyrosine kinase-1-to-placental growth factor ratio were attenuated in the subgroups. Participants in the group with class II or III obesity were 3.13 (95% confidence interval, 1.15-8.49) times more likely than participants with normal weight to have a second-trimester ratio of ≥38 in univariate analysis. CONCLUSION: High early pregnancy body mass index was associated with lower soluble fms-like tyrosine kinase-1 and placental growth factor concentrations across early pregnancy. Maternal body mass was inversely associated with first-trimester soluble fms-like tyrosine kinase-1-to-placental growth factor ratios and positively associated with second-trimester soluble fms-like tyrosine kinase-1-to-placental growth factor ratios, driven by a diminished rise in placental growth factor between the first and second trimesters of pregnancy. Women with class II or III obesity have an increased risk of a high second-trimester soluble fms-like tyrosine kinase-1-to-placental growth factor ratio associated with placental dysfunction.
引用
- Beck C, Allshouse A, Silver RM, et al. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers. Am J Obstet Gynecol MFM. 2022. PMID: 35283347. doi:10.1016/j.ajogmf.2022.100614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。